Diligence memo · auto-generated · as of July 3, 2026
Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Ironwood Pharmaceuticals Inc operates in Pharmaceuticals, based in CAMBRIDGE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ironwood Pharmaceuticals Inc has raised $350M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $175M on 2013-01-04.
Most recent recorded round closed around 2016-09-23.
Valuation (modeled)modeled
Provath models Ironwood Pharmaceuticals Inc at approximately $5.3B (range $714M–$11.6B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.20× the median modeled value of Series D+ Pharmaceuticals companies in 2016–2018 (11 peers) — value vs value, same stage and era. Within the normal band (120% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 17 months.
Last raise 9.8 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 1.2× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 98% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 99% of those peers.
Closest niche peers: Concordia International Corp., Surterra Holdings, Inc./DE, Melinta Therapeutics, Inc. /New/, Beam Therapeutics Inc., Tris Pharma, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.